Naoki Miyashita, Masahiro Onozawa, Shota Yoshida, Hiroyuki Kimura, Shogo Takahashi, Shota Yokoyama, Toshihiro Matsukawa, Shinsuke Hirabayashi, Shinichi Fujisawa, Akio Mori, Shuichi Ota, Yasutaka Kakinoki, Yutaka Tsutsumi, Satoshi Yamamoto, Takuto Miyagishima, Takahiro Nagashima, Makoto Ibata, Kentaro Wakasa, Yoshihito Haseyama, Katsuya Fujimoto, Toshimichi Ishihara, Hajime Sakai, Takeshi Kondo, Takanori Teshima
Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more...
February 28, 2023: International Journal of Hematology